MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Cash and cashequivalents$11,337K (-6.46%↓ Y/Y)Tax creditreceivable$1,681K (-2.38%↓ Y/Y)Prepaid expenses andother current assets$653K (-27.52%↓ Y/Y)In-process research anddevelopment$19,064K (-2.85%↓ Y/Y)Total current assets$13,671K (-7.27%↓ Y/Y)Right of use asset$1,825K (69.45%↑ Y/Y)Property and equipment,net$173K (-32.95%↓ Y/Y)Deposits and other assets$80K (-2.44%↓ Y/Y)Restricted cash$44K (-4.35%↓ Y/Y)Total assets$34,857K (-2.72%↓ Y/Y)Total liabilities andstockholders' equity$34,857K (-2.72%↓ Y/Y)Total liabilities$22,670K (-10.06%↓ Y/Y)Total stockholders'equity$12,187K (14.72%↑ Y/Y)Accumulated deficit-$363,971K (-3.30%↓ Y/Y)Treasury stock at cost,28,810 shares at june...$288K (0.00%↑ Y/Y)Total currentliabilities$12,111K (-2.28%↓ Y/Y)Non-current contingentconsideration$7,169K (-29.44%↓ Y/Y)Loan payable -non-current$1,620K (-1.16%↓ Y/Y)Non-current operating leaseliability$1,374K (135.27%↑ Y/Y)Non-current deferredresearch and development...$396K (-7.91%↓ Y/Y)Additional paid-in capital$376,154K (3.78%↑ Y/Y)Accumulated othercomprehensive loss$247K (-68.85%↓ Y/Y)Common stock, 0.001 parvalue 350,000,000...$45K (462.50%↑ Y/Y)Accrued expenses$6,418K (-28.82%↓ Y/Y)Contingent consideration,current portion$2,650K Deferred research anddevelopment tax...$1,210K (-9.90%↓ Y/Y)Accounts payable$984K (62.11%↑ Y/Y)Operating leaseliability-current portion$525K (185.78%↑ Y/Y)Accrued employeebenefits$290K (-61.79%↓ Y/Y)Loanspayable-current$34K (-39.29%↓ Y/Y)
Balance Sheet

Theriva Biologics, Inc. (TOVX)

Theriva Biologics, Inc. (TOVX)

source: myfinsight.com